Pharmstandard to start production of Roche's Tamiflu in Russia

13 May 2011

Pharmstandard (PHST: MM), Russia's largest pharmaceutical company, has reached an agreement with the Swiss drug major Roche (SIX: ROG) for the production of the firm’s flu drug Tamiflu (oseltamivi) in Russia, the Russian company has recently said. Production is expected to start by the end of the current year.

Tamiflu is one of two drugs, recommended by the World Health Organization for the treatment of swine flu. According to the Russian Vedomosti business paper, in 2010 its global sales amounted to $1 billion, while in 2009 - in the midst of an epidemic – revenues from the drug were $3.68 billion).

May also make GSK’s Relenza

Meanwhile, according to some Russian media reports, in addition to Tamiflu, Pharmstandard also plans to start production of GlaxoSmithKline’s (LSE: GSK) flu drug Relenza (zanamivir), but no final agreement between the sides has been signed yet. Relenza is also backed by the WHO.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK